CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 08/08/24
CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual ConferenceGlobeNewsWire • 06/18/24
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 05/08/24
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)GlobeNewsWire • 05/08/24
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)GlobeNewsWire • 05/07/24
CytomX Therapeutics (CTMX) Surges 214.7%: Is This an Indication of Further Gains?Zacks Investment Research • 05/02/24
CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024GlobeNewsWire • 05/01/24
CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In TownSeeking Alpha • 04/25/24
CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid TumorsGlobeNewsWire • 04/08/24
CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with AstellasGlobeNewsWire • 04/03/24
CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with AstellasGlobeNewsWire • 03/18/24
CytomX Therapeutics Reports 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 03/11/24
CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024GlobeNewsWire • 03/04/24